Cipher Pharmaceuticals Inc (CPH) to Release Quarterly Earnings on Friday
Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) is scheduled to be announcing its earnings results before the market opens on Friday, November 3rd. Analysts expect the company to announce earnings of C$0.18 per share for the quarter.
Shares of Cipher Pharmaceuticals Inc (CPH) opened at 4.37 on Friday. Cipher Pharmaceuticals Inc has a 12 month low of $3.50 and a 12 month high of $5.75. The stock has a 50 day moving average price of $4.62 and a 200-day moving average price of $5.05. The stock’s market cap is $116.33 million.
CPH has been the topic of a number of research reports. TD Securities upped their price target on shares of Cipher Pharmaceuticals from C$5.50 to C$6.50 in a research note on Monday, August 14th. Bloom Burton downgraded shares of Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 14th.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/27/cipher-pharmaceuticals-inc-cph-to-release-quarterly-earnings-on-friday.html.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.